Epizyme Announces Pricing of Public Offering of Common Stock
27 Janvier 2022 - 8:12AM
Business Wire
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated,
commercial-stage biopharmaceutical company developing and
delivering novel epigenetic therapies, today announced the pricing
of an underwritten public offering of 56,666,667 shares of its
common stock at a price to the public of $1.50 per share, before
underwriting discounts. In addition, Epizyme has granted the
underwriters a 30-day option to purchase up to an additional
8,500,000 shares of common stock at the public offering price, less
the underwriting discount. All of the shares in the offering are to
be sold by Epizyme.
Epizyme anticipates the total gross proceeds from the offering
(before deducting underwriting discounts and offering expenses)
will be approximately $85.0 million, excluding any exercise of the
underwriters' options to purchase additional shares.
Epizyme anticipates using the net proceeds from the offering,
together with its existing cash, cash equivalents and marketable
securities, to fund global development and commercialization costs
of tazemetostat outside of Japan, including the costs of conducting
the Company’s ongoing and planned clinical trials of tazemetostat,
including the Company’s confirmatory Phase 1b/3 trials in
epithelioid sarcoma and follicular lymphoma (FL), the Company’s
clinical trials of tazemetostat in additional FL populations and
the Company’s clinical trials of tazemetostat across multiple types
of hematological malignancies and solid tumors; to fund the
Company’s Phase 1/1b trial of its SETD2 inhibitor, EZM0414 and the
discovery and identification of additional product candidates to
expand the Company’s pipeline of novel epigenetic therapies; to
fund initiatives to accelerate commercial adoption of TAZVERIK®;
and for working capital and other general corporate purposes, which
may include the acquisition of companies or businesses or licensing
of other products, businesses or technologies, and repayment and
refinancing of debt.
Jefferies and Barclays are acting as joint bookrunning managers
for the offering. Wedbush PacGrow and H.C. Wainwright & Co. are
acting as co-lead managers. The offering is expected to close on
January 31, 2022, subject to the satisfaction of customary closing
conditions.
The shares are being offered by Epizyme pursuant to a shelf
registration statement that was previously filed with the U.S.
Securities and Exchange Commission (“SEC”) on May 6, 2021 and
declared effective by the SEC on May 13, 2021. The offering is
being made only by means of the written prospectus and prospectus
supplement that form a part of the registration statement. The
preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC on January 26, 2022
and copies of the preliminary prospectus supplement relating to the
offering may be obtained for free by visiting the SEC’s website at
www.sec.gov. Copies of the preliminary prospectus supplement and
the accompanying prospectus relating to the securities being
offered may also be obtained by contacting: Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877)
821-7388, or by email at Prospectus_Department@Jefferies.com; or
Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717 or by email at
barclaysprospectus@broadridge.com or by telephone at (888)
603-5847. The final terms of the offering will be disclosed in a
final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
the securities being offered in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage
biopharmaceutical company committed to its mission of rewriting
treatment for cancer through novel epigenetic medicines. The
Company is focused on creating medicines that are targeted at
specific causes of diseases, that are orally administered,
tolerable, easy to take and based on a deep understanding of the
patients that may benefit from them. The Company aspires to change
the standard-of-care for patients and physicians by developing
medicines with fundamentally new mechanisms of action.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Epizyme, Inc., including statements about
the Company’s public offering, anticipated use of proceeds, future
operations, commercial sales of TAZVERIK, clinical development of
the Company’s therapeutic candidates, expectations regarding future
clinical trials and future expectations and plans and prospects for
the Company and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms or at all;
uncertainties associated with the commercialization of
pharmaceutical products; uncertainties inherent in the initiation
of future clinical studies and in the availability and timing of
data from ongoing clinical studies; whether results from
preclinical studies or earlier clinical studies of the Company’s
product candidates will be predictive of the results of future
trials; whether the Company will receive regulatory approvals,
including accelerated approval, to conduct trials or to market
products; whether the Company's cash resources will be sufficient
to fund the Company’s foreseeable and unforeseeable operating
expenses and capital expenditure requirements; and other factors
discussed in the “Risk Factors” section of the preliminary
prospectus supplement filed with the SEC, the Company’s most recent
Form 10-K and Form 10-Q filed with the SEC and the risks described
in other filings that the Company may make with the SEC. In
addition, the forward-looking statements included in this press
release represent the Company’s views as of the date hereof and
should not be relied upon as representing the Company’s views as of
any date subsequent to the date hereof. The Company anticipates
that subsequent events and developments will cause the Company’s
views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220126006144/en/
Media: Erin Graves media@epizyme.com (617) 500-0615
Investors: Caitlin Stern Real Chemistry
cstern@realchemistry.com
Epizyme (NASDAQ:EPZM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Epizyme (NASDAQ:EPZM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024